InsiderSource

CRYSTAL ROGER

Director, Chief Executive Officer, 10% Owner · SEC CIK 1656633
Insider at MNMD Mind Medicine (MindMed) Inc. OPNT OPIANT PHARMACEUTICALS, INC.
Advertisement

Buy track record

How this insider's open-market purchases have performed
This insider has no open-market purchases in the records we parsed, so there's no buy track record to score. Their full filing history is below.
Advertisement
Open-market buys
$26.6K
2 trades
Open-market sells
$1.99M
18 trades
Net flow
−$1.97M
Net selling
Total filings
39
transactions shown

Full transaction history

All Form 4 activity across every company, newest first
View on SEC EDGAR ↗
OPNT
OPIANT PHARMACEUTICALS, INC.
Sell CRYSTAL ROGER · Director, Chief Executive Officer, 10% Owner · Open-market sale · filed Jan 8, 2019 ΔOwn −48%

Crystal Roger sold $160.2K of OPNT, trimming their stake 48%.

−$160.2K
11,834 sh @ $14
OPNT
OPIANT PHARMACEUTICALS, INC.
Sell CRYSTAL ROGER · Director, Chief Executive Officer, 10% Owner · Open-market sale · filed Oct 10, 2018 ΔOwn −45%

Crystal Roger sold $118.3K of OPNT, trimming their stake 45%.

−$118.3K
6,941 sh @ $17
OPNT
OPIANT PHARMACEUTICALS, INC.
Sell CRYSTAL ROGER · Director, Chief Executive Officer, 10% Owner · Open-market sale · filed Oct 10, 2018 ΔOwn −17%

Crystal Roger sold $53K of OPNT, trimming their stake 17%.

−$53K
3,059 sh @ $17
OPNT
OPIANT PHARMACEUTICALS, INC.
Sell CRYSTAL ROGER · Director, Chief Executive Officer, 10% Owner · Open-market sale · filed Oct 10, 2018 ΔOwn −4.4%

Crystal Roger sold $15.4K of OPNT, trimming their stake 4%.

−$15.4K
847 sh @ $18
OPNT
OPIANT PHARMACEUTICALS, INC.
Sell CRYSTAL ROGER · Director, Chief Executive Officer, 10% Owner · Open-market sale · filed Oct 4, 2018 ΔOwn −17%

Crystal Roger sold $73.8K of OPNT, trimming their stake 17%.

−$73.8K
4,006 sh @ $18
Advertisement
OPNT
OPIANT PHARMACEUTICALS, INC.
Sell CRYSTAL ROGER · Director, Chief Executive Officer, 10% Owner · Open-market sale · filed Oct 4, 2018 ΔOwn −16%

Crystal Roger sold $82.7K of OPNT, trimming their stake 16%.

−$82.7K
4,300 sh @ $19
OPNT
OPIANT PHARMACEUTICALS, INC.
Sell CRYSTAL ROGER · Director, Chief Executive Officer, 10% Owner · Open-market sale · filed Oct 4, 2018 ΔOwn −27%

Crystal Roger sold $177.6K of OPNT, trimming their stake 27%.

−$177.6K
10,144 sh @ $18
OPNT
OPIANT PHARMACEUTICALS, INC.
Buy CRYSTAL ROGER · Director, Chief Executive Officer, 10% Owner · Open-market purchase · filed Jan 19, 2017 ΔOwn +70%

Crystal Roger, OPNT's CEO, spent $24.3K of their own money on 3,475 shares at $7, growing their stake 70%.

+$24.3K
3,475 sh @ $7

Frequently asked questions

How is CRYSTAL ROGER's win rate calculated?

We take every open-market purchase (SEC code P) we can match to a stock price, then compare the split- and dividend-adjusted price on the purchase date to the most recent close. The win rate is the share of those buys currently trading above the purchase price. Sales and share grants are not scored.

Why are some buys not included in the score?

A purchase is excluded if we can't price it — for example if the ticker is missing from the filing, the company has been delisted, or the security isn't a common stock we can match to market data. Excluded counts are shown next to the scored total.

What do the 1M / 3M / 6M / 12M columns mean?

They show each purchase's return after a fixed holding period — one, three, six, and twelve months from the buy date — using split- and dividend-adjusted prices. This separates good entry timing from simply holding a long-running winner. A dash means that horizon hasn't elapsed yet for that trade, or the stock couldn't be priced at that date.

Does a high win rate mean I should copy this insider?

No. Past performance does not predict future results, sample sizes are often small, and an insider's edge in their own company doesn't transfer to yours. This is context, not a recommendation. InsiderSource is not investment advice.

Where does this data come from?

Trades come from CRYSTAL ROGER's SEC Form 4 filings on EDGAR. Prices come from public market data and are split/dividend-adjusted. Always verify against the original filings before acting.